Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« How Not to Do It - Hydrogen Balloons | Main | Bulking Up »

April 26, 2004

Thou Hast It Now. . .

Email This Entry

Posted by Derek

. . .and I fear thou play'dst most foully for it. So Sanofi is really going to get Aventis, and the French government is really going to get their mighty standard-bearer in the drug industry. Bonne chance, guys. I'm not a fan of big drug-company mergers to start with, and this one seems particularly pointless. The Wall Street Journal's coverage sums it up as far as I'm concerned:

"From the start, the battle for Aventis was as much about France's desire to create a home-grown national champion in the pharmaceutical industry as it was about shareholder value and business sense. . .France's intervention in the takeover battle, which runs counter to the free-market principles espoused by the European Union. . ."

"Lip service" translates into all the EU languages, that's for sure. Since when has France ever really been interested in such an Anglo-Saxon concept as a free market? Not when there's national pride at stake, anyway. Look, I understand the desire to have something to point to, to have companies from your own nation be influences on the world. But will this new company be something to be proud of?

The odds are against it. Now that they have this big new Frenchoid drug company (remember, there's a big German contingent, ex-Hoechst), what are they going to do with it? As I've said before, the only way to make the deal make sense, as far as I can see, is for some people to lose their jobs. You know, like most mergers. And since we're certainly not going to have any job cuts in France, and since the German unions have locked their positions up, what's left? (Well, the former Hoechst site in Bridgewater, NJ is left, for one - but if they cut there, this new Francopharma will be doing the complete opposite of all the other major European drug companies.)

Novartis came in at the last minute, but declined to make a bid, which I think was smart of them. Saves a lot of suit jackets from having to be pressed after the French got through twisting their arms, anyway. Novartis's entry may well have driven up the price of the eventual deal, though, and seeing a competitor overpay for an asset must not upset them much, either. If I were more conspiratorial, I'd wonder if that was the whole point of their involvement. . .

Comments (0) + TrackBacks (0) | Category: Business and Markets


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought